Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Neuvotion targets stroke and spinal cord injury rehabilitation with NeuStim commercial launch
Medical Devices & Diagnostics

Neuvotion NeuStim commercialization advances as brain-computer interface research gains validation

Neuvotion links its fall NeuStim launch to a Nature Medicine brain-body interface study, while the implanted system remains investigational.

Read More
AstraZeneca’s investigational CLDN18.2 antibody-drug conjugate sonesitatug vedotin improved overall survival in a Phase 3 trial involving previously treated advanced gastric and gastroesophageal junction cancers, although the progression-free survival endpoint was not statistically significant. Representative image.
Pharma & Biotech

Sonesitatug vedotin Phase 3 survival win strengthens AstraZeneca’s gastric cancer ADC strategy

Read why AstraZeneca’s sonesitatug vedotin survival win in CLDN18.2-positive gastric cancer is tempered by a Phase 3 PFS miss.

Read More
Johnson & Johnson’s proposed $5.5 billion settlement aims to resolve about 76,000 existing ovarian talc litigation claims, subject to the required claimant participation. Representative image.
Pharma & Biotech

Could Johnson & Johnson’s $5.5bn talc deal finally close a 15-year legal overhang?

Johnson & Johnson proposes a $5.5 billion deal for 76,000 ovarian talc claims, but participation, future lawsuits and costs remain critical.

Read More
SCIEX’s ExionLC MD and clinical SCIEX OS platform aim to accelerate LC-MS/MS testing by automating data review, managing analytical exceptions and streamlining clinical laboratory workflows. Representative image.
Medical Devices & Diagnostics

SCIEX expands clinical diagnostics portfolio with ExionLC MD and SCIEX OS software

SCIEX launches ExionLC MD and clinical SCIEX OS software to automate LC-MS/MS workflows, reduce manual review and improve lab throughput.

Read More
Akeso has dosed the first patient in a Phase Ib/II study evaluating the HER3 antibody-drug conjugate AK138D1 with ivonescimab in advanced non-small cell lung cancer. Representative image.
Pharma & Biotech

What Akeso’s AK138D1 and ivonescimab combination must prove in advanced NSCLC

Akeso has started a Phase Ib/II lung cancer trial of HER3 ADC AK138D1 with ivonescimab. See what the combination must prove.

Read More
ViiV Healthcare’s two-drug Dovato regimen matched the three-drug Biktarvy regimen for viral suppression at Week 48 in the head-to-head VOGUE HIV study. Representative image.
Pharma & Biotech

ViiV Healthcare challenges three-drug HIV standard with positive Dovato VOGUE data

ViiV Healthcare’s VOGUE trial found Dovato non-inferior to Biktarvy at Week 48, sharpening the debate over two-drug first-line HIV care.

Read More
A clinical research setting illustrates Arrowhead Pharmaceuticals’ Phase 3 YOSEMITE trial evaluating zodasiran for homozygous familial hypercholesterolemia following completion of global patient enrollment. Representative image.
Pharma & Biotech

Arrowhead has enrolled 70 patients in a rare cholesterol trial, but can zodasiran clear the Phase 3 bar?

Arrowhead completes Phase 3 YOSEMITE enrollment as zodasiran faces a crucial test of LDL cholesterol lowering in patients with severe HoFH.

Read More
Thermo Fisher Scientific’s ADLM 2026 showcase highlights integrated diagnostic testing, laboratory automation, quality controls and digital workflows designed to support modern clinical laboratories. Representative image.
Medical Devices & Diagnostics

Thermo Fisher Scientific expands specialty diagnostics strategy with EXENT and EliA CTD 13 Screen

Thermo Fisher’s ADLM 2026 showcase links new diagnostics, lab quality tools and workflow scale, while active device corrections test execution.

Read More
Otsuka’s VOYXACT Phase 3 VISIONARY trial is moving into a decisive stage as two-year eGFR results assess whether sibeprenlimab can preserve kidney function in adults with IgA nephropathy. Representative image.
Pharma & Biotech

Can VOYXACT move beyond proteinuria? Otsuka’s two-year VISIONARY data may decide its FDA future

Otsuka will unveil two-year VISIONARY eGFR data for VOYXACT, a pivotal test of kidney preservation and its path to full FDA approval.

Read More
Novanta Inc.’s $1.2 billion acquisition of Riverpoint Medical expands its position in surgical consumables, implantable materials and minimally invasive medical device manufacturing. Representative image.
Medical Devices & Diagnostics

Novanta just made a $1.2bn surgical consumables bet. Can Riverpoint justify the price?

Novanta completes Riverpoint Medical acquisition, expanding surgical consumables and recurring revenue. See what integration and returns must deliver.

Read More